WellSpring Completes $3M Investment, Enters IDT Australia Pact
04.26.16
Adds capabilities with new equipment and will produce several products for U.S. market
WellSpring Pharma Services (Booth 1212) has completed a $3 million capital investment in new equipment and has entered a strategic partnership with IDT Australia Ltd. to manufacture drugs for the U.S. market.
The investment adds capabilities in smaller development-scale equipment, expanded manufacturing for specialized dosage forms, such as bilayer tablets, and improved support for high-potency compound manufacturing. New equipment includes: an Alexanderwerk Roller Compactor; an IMA Precisa capsule weight checker; a 400 kg O’Hara Tray Drying oven; a Korsch XL 400 Tablet Press with bilayer module; a Glatt GPCG 2/5 Fluid Bed Processor; an O’Hara Aqueous Film Coater with 18” and 30” interchangeable pans; and a 5L Becomix Counter sweep vessel.
Additionally, WellSpring signed a manufacturing and supply agreement to produce several products for IDT Australia at its facility near Toronto, including Pindolol, a cardiac drug with an estimated U.S. market value of $10 million.
“Our expanded capabilities include new expertise in process development and manufacturing for earlier phased clinical trials as well as future expansion of our large-scale manufacturing capabilities,” said David Mayers, president, WellSpring Pharma Services. “We’re now better equipped to offer our clients services from small-scale development and scale-up to large-scale manufacturing, packaging and distribution.”
WellSpring will be showcasing its capital expansion as well as its new branding at INTERPHEX. Key WellSpring executives will also be among the speakers at INTERPHEX with three presentations on Wednesday, April 27.
The investment adds capabilities in smaller development-scale equipment, expanded manufacturing for specialized dosage forms, such as bilayer tablets, and improved support for high-potency compound manufacturing. New equipment includes: an Alexanderwerk Roller Compactor; an IMA Precisa capsule weight checker; a 400 kg O’Hara Tray Drying oven; a Korsch XL 400 Tablet Press with bilayer module; a Glatt GPCG 2/5 Fluid Bed Processor; an O’Hara Aqueous Film Coater with 18” and 30” interchangeable pans; and a 5L Becomix Counter sweep vessel.
Additionally, WellSpring signed a manufacturing and supply agreement to produce several products for IDT Australia at its facility near Toronto, including Pindolol, a cardiac drug with an estimated U.S. market value of $10 million.
“Our expanded capabilities include new expertise in process development and manufacturing for earlier phased clinical trials as well as future expansion of our large-scale manufacturing capabilities,” said David Mayers, president, WellSpring Pharma Services. “We’re now better equipped to offer our clients services from small-scale development and scale-up to large-scale manufacturing, packaging and distribution.”
WellSpring will be showcasing its capital expansion as well as its new branding at INTERPHEX. Key WellSpring executives will also be among the speakers at INTERPHEX with three presentations on Wednesday, April 27.
